Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Retinal blood flow and oxygen saturation before and after intravitreal aflibercept for diabetic macular edema
Author Affiliations & Notes
  • Ayaka Hara
    ophthalmology, Kagawa Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Kita-gun, Kagawa, Japan
  • Yuta Koyama
    ophthalmology, Kagawa Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Kita-gun, Kagawa, Japan
  • Yukiko Miyoshi
    ophthalmology, Kagawa Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Kita-gun, Kagawa, Japan
  • Isao Ueno
    ophthalmology, Kagawa Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Kita-gun, Kagawa, Japan
  • Rie Osaka
    ophthalmology, Kagawa Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Kita-gun, Kagawa, Japan
  • Yuki Nakano
    ophthalmology, Kagawa Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Kita-gun, Kagawa, Japan
  • Kiyoshi Suzuma
    ophthalmology, Kagawa Daigaku Igakubu Daigakuin Igakukei Kenkyuka, Kita-gun, Kagawa, Japan
  • Footnotes
    Commercial Relationships   Ayaka Hara None; Yuta Koyama None; Yukiko Miyoshi None; Isao Ueno None; Rie Osaka None; Yuki Nakano None; Kiyoshi Suzuma CHUGAI PHARMACEUTICAL, Novartis Pharmaceuticals, Bayer Pharma, Regeneron Pharmaceuticals, SCD, Bioeq GmbH, Santen Pharmaceutical Co,ALCON JAPAN LTD, Senju Pharmaceutical, pfizer, HOYA, AMO, Kowa, JFE, Tomey, Code F (Financial Support), Novartis Pharmaceuticals, Bayer Pharma, Santen Pharmaceutical Co, ALCON JAPAN LTD, Senju Pharmaceutical, HOYA, Kowa, AMO, Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6224. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ayaka Hara, Yuta Koyama, Yukiko Miyoshi, Isao Ueno, Rie Osaka, Yuki Nakano, Kiyoshi Suzuma; Retinal blood flow and oxygen saturation before and after intravitreal aflibercept for diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6224.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To examine changes in retinal blood flow and retinal vascular oxygen saturation (SatO2) before and after intravitreal aflibercept (IVA) for diabetic macular edema (DME).

Methods : The subjects were 21 patients and 21 eyes that underwent IVA for DME. IVA was performed once a month for three months. Blood flow was measured using Laser Speckle Flowgraphy (LSFG) and retinal SatO2 was measured using Oxymap T1 before IVA (0M), 1 month (1M), 2 months (2M) and 3 months (3M) after the start of treatment.

Results : Retinal blood flow and SatO2 are shown in the order 0M, 1M, 2M, and 3M. The mean blur rate (MBR) for the vascular regions were 28.0±10.1, 25.8±9.1, 25.4±8.3, 24.7±8.6. It was significantly lower at 3M than at 0M (p=0.03). Mean arterial SatO2 was 99.0 ± 7.6%, 100.0 ± 9.3%, 100.2 ± 9.4%, and 99.6 ± 10.0%. Mean venous SatO2 was 55.6 ± 7.6%, 56.9 ± 9.3%, 56.2 ± 9.4%, and 55.3 ± 10.0%. Mean arteriovenous difference was 43.4 ± 11.1%, 43.1 ± 13.4%, 44.0 ± 12.4%, and 44.3 ± 12.8%. Mean arterial SatO2, mean venous SatO2, and mean arteriovenous difference showed no significant differences during follow-up. Significant correlations were found between arteriovenous difference and MBR at 0M, 1M and 2M (r=-0.604, p=0.006; r=-0.626, p=0.004; r=-0.612, p=0.005), but not at 3M (r=-0.359, p=0.13).

Conclusions : IVA for DME reduced retinal blood flow. and weakened the correlation between retinal blood flow and SatO2 arteriovenous difference.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×